陽普醫療:子公司變更醫療器械生產許可證 並在產品登記表增加“醫用外科口罩”
格隆匯2月10日丨陽普醫療(300030.SZ)公佈,2020年2月10日,公司全資子公司陽普醫療(湖南)有限公司(“湖南陽普”)收到了由湖南省藥品監督管理局換髮的《醫療器械生產許可證》,此次變更主要涉及生產範圍,並在附件《醫療器械生產產品登記表》增加一項生產產品“醫用外科口罩”(註冊號:湘械注準20202140090)。
變更後的生產許可證生產範圍為II類:22-11採樣設備和器具;III類:14-02血管內輸液器具;舊版II類:血液化驗設備和器具-6842-4;舊版III類:注射穿刺器械-6815。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.